4:32 PM ET
10-Q
Financial Results
Humacyte Q3 2026 Results: Net Loss of $15.5M, Loss Narrows
Humacyte, Inc. reported a significant increase in cash and cash equivalents to $64.5 million as of September 30, 2026, following the commercialization of Symvess. The company recorded a litigation settlement liability of $9.75 million and an accumulated deficit of $796.8 million, while common stock outstanding grew to over 277 million shares.
- Key figure
- Net loss $15.5M